Nektar Therapeutics
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar is headquartered in San Francisco, California.
Current Price
$70.62
-4.99%Profile
Valuation (TTM)
Market Cap$2.03B
P/E-12.81
EV—
P/B22.55
Shares Out28.69M
P/Sales36.42
Revenue$55.63M
EV/EBITDA—
Nektar Therapeutics (NKTR) Stock News
NKTR Stock News & Headlines
Latest stock news and headlines for Nektar Therapeutics (NKTR). Stay informed on earnings reports, analyst upgrades and downgrades, market-moving events, and company announcements.
Current stock price: $70.62. Market cap: $2.03B. Sector: Healthcare. Industry: Biotechnology. This page aggregates the latest news articles relevant to NKTR from financial news sources, helping investors stay current on events that may impact Nektar Therapeutics's stock price.
News catalysts can drive significant short-term price movement. Earnings surprises, management changes, product launches, regulatory decisions, and analyst coverage changes all create opportunities and risks. Combine news monitoring with GoodMoat's fundamental analysis, quality scores, and valuation tools for a complete research workflow on Nektar Therapeutics (NKTR).